Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10091381 | 0.85 | CES2 (0.45) | CES2CES1ADRA2AADRA2BADRA2C | |
| SCHEMBL20237842 | 0.83 | PDE2A (0.53) | CES2CES1PDE2ALMNATP53 | |
| SCHEMBL7983483 | 0.83 | PDE2A (0.53) | CES2CES1PDE2ALMNATP53 | |
| SCHEMBL29669152 | 0.83 | PDE2A (0.53) | CES2CES1PDE2ALMNATP53 | |
| SCHEMBL7786189 | 0.83 | CES2 (0.44) | CES2CES1ADRA2AADRA2BADRA2C | |
| SCHEMBL1068333 | 0.82 | ADRA2A (0.67) | ADRA2AADRA2BADRA2CPDE2AADRB1 | |
| SCHEMBL8746393 | 0.82 | CES2 (0.42) | CES2CES1ADRA2AADRA2BADRA2C | |
| SCHEMBL7153251 | 0.82 | ADRA2C (0.53) | CES2CES1ADRA2AADRA2BADRA2C | |
| SCHEMBL15915397 | 0.81 | CFD (0.47) | ADRA2AADRA2BADRA2CPDE2AADRB1 | |
| SCHEMBL6744226 | 0.81 | PDE2A (0.44) | CES2CES1ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | CES2 455/4885CES1 532/4885ADRA2A 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.